Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 49 Sarcoma 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasms 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Ovarian Neoplasms 4 Lymphoma, Non-Hodgkin 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Osteosarcoma 3 Neuroblastoma 3 Multiple Myeloma 3 Medulloblastoma 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Prostatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma 2 Liposarcoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Head and Neck Neoplasms 2 Glioma 2 Estrogen Receptor-positive Breast Cancer 2 Ependymoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Chordoma 2 Carcinoma, Squamous Cell 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡